{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T17:19:06Z","timestamp":1762017546542},"reference-count":24,"publisher":"Informa UK Limited","issue":"12","funder":[{"name":"NIH\/NINDS program project","award":["3P50 NS16308-15A1"],"award-info":[{"award-number":["3P50 NS16308-15A1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.2217\/pgs.11.105","type":"journal-article","created":{"date-parts":[[2011,11,2]],"date-time":"2011-11-02T13:01:28Z","timestamp":1320238888000},"page":"1671-1679","source":"Crossref","is-referenced-by-count":42,"title":["Functional Analysis of UGT1A4\n            <sup>P24T<\/sup>\n            and UGT1A4\n            <sup>L48V<\/sup>\n            Variant Enzymes"],"prefix":"10.1080","volume":"12","author":[{"given":"Jin","family":"Zhou","sequence":"first","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, 06877, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Upendra A","family":"Argikar","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Inc., Cambridge, MA02139, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rory P","family":"Remmel","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, University of Minnesota, Minneapolis, MN55455, USA. Tel.:"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2011,11,25]]},"reference":[{"key":"e_1_3_4_3_1_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500171"},{"key":"e_1_3_4_3_2_1","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.9.6.703"},{"key":"e_1_3_4_3_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602042"},{"key":"e_1_3_4_3_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-008-0821-z"},{"key":"e_1_3_4_3_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20131"},{"key":"e_1_3_4_3_6_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.32.1.72"},{"key":"e_1_3_4_3_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3283331637"},{"key":"e_1_3_4_3_8_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.002576"},{"key":"e_1_3_4_3_9_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.20.144"},{"key":"e_1_3_4_3_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1539"},{"key":"e_1_3_4_3_11_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.028712"},{"key":"e_1_3_4_3_12_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.022426"},{"issue":"7","key":"e_1_3_4_3_13_1","first-page":"1029","volume":"29","author":"Hutzler JM","year":"2001","unstructured":"Hutzler JM , HauerMJ, TracyTS. Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. Drug Metab. Dispos.29(7) , 1029\u20131034 (2001).","journal-title":"Drug Metab. Dispos."},{"issue":"12","key":"e_1_3_4_3_14_1","first-page":"1644","volume":"29","author":"Kenworthy KE","year":"2001","unstructured":"Kenworthy KE , ClarkeSE, AndrewsJ, HoustonJB. Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab. Dispos.29(12) , 1644\u20131651 (2001).","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_4_3_15_1","unstructured":"Segel I . Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. Wiley Classics Library NJ USA (1993)."},{"key":"e_1_3_4_3_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811263392207"},{"issue":"7","key":"e_1_3_4_3_17_1","first-page":"493","volume":"6","author":"Flockhart D","year":"2008","unstructured":"Flockhart D . CYP2D6 genotyping and the pharmacogenetics of tamoxifen. Clin. Adv. Hematol. Oncol.6(7) , 493\u2013494 (2008).","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"e_1_3_4_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2004.02.014"},{"key":"e_1_3_4_3_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3219"},{"key":"e_1_3_4_3_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1987.193"},{"key":"e_1_3_4_3_21_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.106.009340"},{"key":"e_1_3_4_3_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498250902745082"},{"key":"e_1_3_4_3_23_1","first-page":"229","volume":"51","author":"Gulcebi IOM","year":"2010","unstructured":"Gulcebi IOM , OzkaynakciA, OzkaraC, GulhanR, OnatF. Plasma lamotrigine levels of patients with polymorphic UGT1A4 enzymes. Epilepsia51(Suppl. 4) , 229 (2010).","journal-title":"Epilepsia"},{"key":"e_1_3_4_4_2_1","unstructured":"Bock KW Burchell B Guillemette C et al. UGT Alleles nomenclature home page. www.ugtalleles.ulaval.ca"}],"container-title":["Pharmacogenomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/pgs.11.105","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T19:30:34Z","timestamp":1715974234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/pgs.11.105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,25]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["10.2217\/pgs.11.105"],"URL":"https:\/\/doi.org\/10.2217\/pgs.11.105","relation":{},"ISSN":["1462-2416","1744-8042"],"issn-type":[{"value":"1462-2416","type":"print"},{"value":"1744-8042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,25]]}}}